Comparative Efficacy of Peptides vs. Anabolic Steroids

Apples to Oranges: Why This Isn't a Fair Fight

Peptides and anabolic-androgenic steroids (AAS) get compared constantly, usually to ask whether peptides can replace steroids. For adding muscle, the human evidence says they can't. AAS act directly on the androgen receptor in muscle and almost every other tissue. The peptides in this comparison work upstream or on narrower pathways. Growth hormone secretagogues prompt the pituitary to release more of the body's own growth hormone (GH), and repair peptides like BPC-157 appear, in animal studies, to act on blood vessel growth and inflammation at an injury site.

That difference explains most of the gap in results and side effects. It also explains a gap in evidence: testosterone has decades of randomized human trials, while most of the peptides lifters compare it with have limited human data, and some have none.

The Hypertrophy Question: Where Steroids Are King

The best-known human data on AAS and muscle comes from a 1996 trial in the New England Journal of Medicine. Researchers gave 43 healthy men 600 mg of testosterone enanthate or placebo weekly for 10 weeks, with or without supervised weight training. Men given testosterone plus training gained about 6.1 kg of fat-free mass and added about 22 kg to their bench press. Even the men who took testosterone without training gained more muscle size and strength than either placebo group.

Growth hormone looks very different. A 2008 systematic review in the Annals of Internal Medicine pooled 27 study samples of GH given to young, fit adults. Lean body mass rose by about 2.1 kg, but strength and exercise capacity didn't improve, and the GH groups had more soft-tissue swelling and fatigue. A 2010 study offers one explanation: two weeks of GH raised collagen synthesis in tendon and muscle but didn't change myofibrillar protein synthesis, the process that builds contractile muscle.

Secretagogues such as ipamorelin, CJC-1295 and GHRP-2 raise GH less than injected GH does, because release stays pulsatile and subject to feedback. A 2018 review found few long-term controlled trials of these compounds and flagged a concern about rising blood glucose. Human data on ipamorelin is especially thin. FDA's October 2024 advisory committee review describes one IV pharmacokinetic study and a Phase 2 trial in 117 surgical patients that missed its primary endpoint, after which development stopped.

Users who run secretagogue stacks commonly describe better sleep and recovery with slow body-composition changes, not rapid weight gain. No trial has compared a secretagogue stack with a testosterone cycle.

Fat Loss: What the Evidence Shows

AAS can improve body composition by adding lean mass, but fat loss is a by-product of that, and it comes with the risks covered below. Peptides are often marketed as a more targeted option for cutting. How well that holds up depends on the compound.

AOD-9604 is a modified fragment from the C-terminal end of human growth hormone (amino acids 176-191). In obese mice, 14 days of AOD-9604 injections reduced body weight and body fat. The human trials didn't hold up. According to FDA's December 2024 advisory committee briefing, the largest trial, OPTIONS, enrolled 536 adults with obesity who took oral AOD-9604 (0.25, 0.5 or 1 mg daily) or placebo for 24 weeks. It found no significant difference in weight loss at the 12-week primary endpoint, and the developer ended its obesity program in February 2007. All human trials used oral or IV dosing; FDA found no human data for subcutaneous injection, which is how users take it, and said the limited safety data don't support definitive conclusions. User reports are mixed, and many describe little noticeable change.

Tesamorelin, a GHRH analog, is the one compound here with an FDA approval tied to fat. Its label covers reducing excess abdominal fat in adults with HIV-associated lipodystrophy. In the two main trials, 2 mg daily for 26 weeks reduced visceral fat by about 21-27 square centimeters on CT, versus essentially no change on placebo. The label says it isn't indicated for weight loss because its effect on body weight is neutral, and it hasn't been tested in lean, healthy lifters.

Users also commonly report fat loss on GH secretagogue stacks, which fits GH's known effect on lipolysis, but we found no controlled trial in healthy adults that measured it.

Connective Tissue and Injury Repair

This is where peptides get the most attention from lifters, and where the evidence leans hardest on animal studies.

BPC-157 is a 15-amino-acid peptide (a pentadecapeptide) derived from a protein in gastric juice. In a 2006 rat study, daily BPC-157 improved healing after the Achilles tendon was cut from the heel bone, with higher load to failure and better-organized collagen. A 2025 systematic review in HSS Journal found 36 relevant studies, and 35 were preclinical. The only clinical one was a retrospective series in which 7 of 12 patients with knee pain reported relief lasting more than six months. The review found no clinical safety data. Users report everything from clear improvement within weeks to no change at all, and product quality makes those reports hard to interpret.

TB-500 isn't the same thing as thymosin beta-4. It's a synthetic, N-acetylated fragment covering residues 17-23 of the 43-amino-acid protein, first characterized by anti-doping laboratories. Human trials, such as eye-drop studies, have tested the full-length protein. As of October 2026, FDA says it has identified no human exposure data for the TB-500 fragment, so claims about cell migration and blood vessel growth come from research on full thymosin beta-4, mostly in animals and cell culture.

AAS don't appear to act on these repair pathways. The Endocrine Society's 2014 statement on performance-enhancing drugs lists musculoskeletal disorders among the harms linked to AAS use, and a common worry on lifting forums is that tendons don't keep pace when strength rises quickly. Some lifters add repair peptides for that reason, though no study has tested the combination.

The Price of Power: Systemic vs. Specific Effects

AAS side effects are well documented. Exogenous testosterone suppresses the body's own production through negative feedback on the pituitary, which is why users plan post-cycle therapy. The Endocrine Society statement links AAS use to a higher risk of death and to cardiovascular, psychiatric and liver disorders, and notes that most users are non-athlete weightlifters taking doses above those tested in trials.

Peptides carry a different risk profile, but calling it milder is only partly supported:

• GH secretagogues: Trials and users report water retention, numb or tingling hands, and higher blood glucose. Users know GHRP-6 for intense hunger, and older GHRPs can raise cortisol and prolactin. Because release stays pulsatile, secretagogues don't shut down natural hormone production the way AAS do, but long-term data in healthy adults is missing.
• Repair peptides (BPC-157, TB-500): Rodent studies haven't shown clear toxicity, but no study has tracked adverse events in people over months or years, and FDA says it lacks the information to know whether either would cause harm. The more immediate risk is the product: purity and sterility vary between research-chemical sources. Our guide to how peptide vials are tested for purity explains what a certificate of analysis can and can't show.

Testosterone acts on androgen receptors throughout the body, while ipamorelin binds mainly to the ghrelin receptor (GHS-R1a) in the pituitary. A narrower target should mean fewer off-target effects, but the long-term human data to confirm it doesn't exist for most peptides. Our article on long-term health risks of peptide use covers what is known.

Stability: Why Handling Changes Peptide Results

Testosterone cypionate is a small, stable molecule in oil, designed to release slowly over days. A lyophilized peptide is a folded chain of amino acids whose function depends on its structure, and once it's reconstituted, heat, agitation and time break it down. Peptides also clear quickly: preclinical data put BPC-157's half-life under 30 minutes.

So a weak result may reflect handling or a mislabeled vial rather than the compound. A peptide stored warm or kept too long after mixing delivers less than its label says. Our peptide reconstitution and storage guide covers sterile mixing and storage.

Sport and Regulatory Status

As of October 2026, WADA's 2026 Prohibited List bans every compound on this page at all times: AAS under S1.1, BPC-157 under S0, AOD-9604 under S2.2.3, CJC-1295, tesamorelin and ipamorelin under S2.2.4, and TB-500 under S2.3. Our overview of peptide rules in sport covers testing.

Tesamorelin is the only peptide here with an FDA approval, and only for HIV-associated lipodystrophy. FDA's compounding safety page, updated in April 2026, lists AOD-9604, BPC-157 and the TB-500 fragment as withdrawn nominations and says the agency lacks enough safety information to know whether they would harm people.

Comparison table

What We Still Don't Know

• No trial has compared any peptide with AAS head to head for muscle, fat loss or injury recovery.
• Whether BPC-157's rodent tendon results carry over to people. As of October 2026, a University of Arkansas Phase 1 trial in rotator cuff repair (NCT07803250, about 30 patients) is registered with a planned start in January 2027.
• How full-length thymosin beta-4 performs in its ongoing Phase 3 eye-drop trial (SEER-2), and whether any of it applies to the untested TB-500 fragment.